Logomenu
shrug

Do you need help with

A randomized open-label clinical trial was carried out to determine the efficacy and safety of Crizotinib (250 mg twice daily), an oral kinase inhibitor, versus standard i.v. chemotherapy (75 mg docetaxel every 3 weeks) in a cohort of patients with locally advanced or metastatic ALK-positive (anaplastic lymphoma kinase - a tyrosine kinase known to be involved in this cancer) lung cancer. The primary outcome measure was progression free survival after 24 months. Patients were recruited in multiple centres across Europe, North America and Asia based on their genotype for the alk gene.What are the main characteristics of the clinical trial phase preceding this one?

Then try StudyFetch, the AI-powered platform that can answer your questions and teach you more about it!

arrowarrow
Learn The Answer

How StudyFetch Helps You Master This Topic

AI-Powered Explanations

Get in-depth, personalized explanations on this topic and related concepts, tailored to your learning style.

Practice Tests

Take adaptive quizzes that focus on your weak areas and help reinforce your understanding of the subject.

Interactive Flashcards

Review key concepts and terms with AI-generated flashcards, optimizing your retention and recall.

Educational Games

Engage with fun, interactive games that reinforce your learning and make studying more enjoyable.

Start mastering this topic and many others with StudyFetch's comprehensive learning tools.

study fetcharrow
Ready To ace that test?

Sign up to revolutionize your learning.